Application of human adipose-derived stem cell-derived exosomes hADSCs-EVs in the preparation of drugs for the treatment of severe acute pancreatitis
The immune microenvironment of pancreatic tissue is regulated by human adipose stem cell-derived exosome hADSCs-EVs, which solves the problems of tissue damage repair and organ function improvement in severe acute pancreatitis, significantly reduces mortality and provides a new treatment direction.
Patent Information
- Application Number
- CN202310624671.4
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2023-05-30
- Publication Date
- 2024-11-19
- Estimated Expiration
- 2043-05-30
AI Technical Summary
The prior art lacks effective methods for repairing tissue damage and improving organ function to treat severe acute pancreatitis, resulting in high mortality.
Human adipose stem cell-derived exosome hADSCs-EVs are used to regulate the number of immune cells and factor expression in pancreatic tissues, improve the immune microenvironment, promote tissue repair and improve organ function.
It significantly improved tissue repair and organ function of severe acute pancreatitis, reduced mortality, and provided a new treatment direction.
Smart Images

Figure CN118126942B_ABST
Abstract
Description
Technical Field
[0001] The present invention relates to the field of biomedicine technology, and in particular to the use of human adipose stem cell-derived exosomes (hADSCs-EVs) in the preparation of drugs for treating severe acute pancreatitis. Background Art
[0002] Acute pancreatitis (AP) is a common clinical emergency and critical disease, which originates from the activation of pancreatic enzymes in pancreatic acinar cells under the action of various causes, leading to digestion of pancreatic tissue itself. Some AP patients only have local self-limited damage to the pancreas, while up to 10%-20% of AP patients develop systemic multi-organ dysfunction as the disease progresses, and develop into severe acute pancreatitis (SAP). At present, the main clinical treatment methods are anti-inflammatory, inhibition of pancreatic enzyme secretion, fluid resuscitation, infection control and nutritional support. There is still a lack of long-term effective methods for tissue damage repair and organ function improvement. Summary of the invention
[0003] In view of the defects in the prior art, the purpose of the present invention is to provide the use of human adipose stem cell-derived exosomes hADSCs-EVs in the preparation of drugs for the treatment of severe acute pancreatitis. The human adipose stem cell-derived exosomes hADSCs-EVs in the drugs for the treatment of severe acute pancreatitis can improve the immune microenvironment state of pancreatic tissue in the early stage of severe acute pancreatitis, promote tissue repair and organ function improvement after severe acute pancreatitis damage, and provide a new direction for clinically improving the prognosis of severe acute pancreatitis and reducing mortality.
[0004] The first aspect of the present invention provides a method for preparing human adipose stem cell-derived exosomes hADSCs-EVs, comprising the following steps:
[0005] hADSCs cells were inoculated in a culture dish and cultured using exosome-free serum culture medium until the cell confluence reached 100%. The supernatant was collected, ultracentrifuged, the precipitate was retained, and resuspended to obtain adipose stem cell-derived exosomes hADSCs-EVs.
[0006] A second aspect of the present invention provides human adipose stem cell-derived exosomes hADSCs-EVs, which are prepared using the above method.
[0007] The third aspect of the present invention provides the use of the above-mentioned human adipose stem cell-derived exosomes hADSCs-EVs in the preparation of drugs for treating acute pancreatitis and / or severe acute pancreatitis.
[0008] In one embodiment of the present invention, the human adipose stem cell-derived exosomes hADSCs-EVs in the drug for treating acute pancreatitis and / or severe acute pancreatitis regulate the number of immune cells infiltrating in the pancreatic tissue and / or the expression levels of pro-inflammatory factors and / or the expression levels of anti-inflammatory factors, thereby regulating the immune microenvironment.
[0009] In one embodiment of the present invention, the immune cells infiltrating the pancreatic tissue are at least one of Treg, Th2, Th1, Th17, M1, and M2.
[0010] In one embodiment of the present invention, the pro-inflammatory factor is at least one of IFN-γ, IL-1β, and IL-18.
[0011] In one embodiment of the present invention, the anti-inflammatory factor is IL-10.
[0012] A fourth aspect of the present invention provides the use of the above-mentioned human adipose stem cell-derived exosomes hADSCs-EVs in the preparation of exosome preparations having immune microenvironment regulating effects.
[0013] Compared with the prior art, the embodiments of the present invention have the following beneficial effects:
[0014] 1. The human adipose stem cell-derived exosomes hADSCs-EVs prepared by the preparation method provided in the embodiment of the present invention can improve the immune microenvironment of pancreatic tissue in the early stage of severe acute pancreatitis, promote tissue repair and organ function improvement after severe acute pancreatitis damage, and provide a new direction for clinically improving the prognosis of severe acute pancreatitis and reducing mortality.
[0015] 2. The embodiment of the present invention provides a preparation method for preparing human adipose stem cell-derived exosomes hADSCs-EVs, which are used in the preparation of drugs for treating acute pancreatitis and / or severe acute pancreatitis, and the immune microenvironment is regulated by regulating the expression levels of infiltrating immune cells and / or pro-inflammatory factors and / or anti-inflammatory factors in the pancreatic tissue.
[0016] 3. The human adipose stem cell-derived exosomes hADSCs-EVs prepared by the preparation method provided in the embodiment of the present invention can also be used to prepare exosome preparations with immune microenvironment regulation effects, thereby achieving immune microenvironment regulation effects by regulating the expression levels of infiltrating immune cells and / or pro-inflammatory factors and / or anti-inflammatory factors in pancreatic tissue. BRIEF DESCRIPTION OF THE DRAWINGS
[0017] Other features, objects and advantages of the present invention will become more apparent from the detailed description of non-limiting embodiments made with reference to the following drawings:
[0018] Figure 1 This is the electron microscopy result of hADSCs-EVs;
[0019] Figure 2 This is the result of Western Blot detection of hADSCs-EVs surface markers;
[0020] Figure 3 It is the particle size distribution diagram of hADSCs-EVs, where the abscissa represents the particle diameter distribution and the ordinate represents the particle concentration;
[0021] Figure 4 The distribution and fluorescence intensity of hADSCs-EVs in various tissues and organs of mice;
[0022] Figure 5 This is the survival curve of SAP mice;
[0023] Figure 6 HE staining of pancreatic tissue of SAP mice;
[0024] Figure 7 This is a graph showing changes in serum lipase and amylase levels in SAP mice;
[0025] Figure 8 This is a graph showing changes in serum inflammatory cytokine levels in SAP mice;
[0026] Fig. 9 This is a graph showing the changes in the proportion of Treg cells in the pancreatic tissue of SAP mice;
[0027] Fig.10 This is a graph showing the changes in the proportion of Th2 cells in the pancreatic tissue of SAP mice;
[0028] Fig.11 This is a graph showing the changes in the proportion of Th1 cells in the pancreatic tissue of SAP mice;
[0029] Fig.12 This is a graph showing the changes in the proportion of Th17 cells in the pancreatic tissue of SAP mice;
[0030] Fig.13 This is a graph showing the changes in the proportion of macrophages in the pancreatic tissue of SAP mice;
[0031] Fig.14 This is a diagram showing the uptake of hADSCs-EVs by Treg cells;
[0032] Fig.15 Independent induction of hADSCs-EVs CD4+T cell Foxp3 and IL-10 expression diagram;
[0033] Fig.16 Induction agent combined with hADSCs-EVs induction CD4+T cell Foxp3 and IL-10 expression diagram;
[0034] Fig.17 Independent induction of hADSCs-EVs Diagram of CD4+T cells differentiation into Treg cells;
[0035] Fig.18 Independent induction of hADSCs-EVs Diagram of CD4+T cell differentiation into Th2 cells. DETAILED DESCRIPTION
[0036] In this article, the range expressed by "a value to another value" is a summary expression method to avoid listing all the values in the range one by one in the specification. Therefore, the description of a specific numerical range covers any value in the numerical range and a smaller numerical range defined by any value in the numerical range, just as if the arbitrary value and the smaller numerical range were explicitly written in the specification.
[0037] Acute pancreatitis (AP) is a common clinical emergency and critical disease, which originates from the activation of pancreatic enzymes in pancreatic acinar cells under the action of various causes, leading to digestion of pancreatic tissue. Some AP patients only have local self-limited damage to the pancreas, while up to 10%-20% of AP patients develop systemic multi-organ dysfunction as the disease progresses, developing into severe acute pancreatitis (SAP).
[0038] The accumulation of local inflammatory cells in pancreatic tissue is an important pathophysiological basis for early SAP damage and a driving factor for the severity of SAP. In the early stage of SAP, pancreatic damage is caused by the activation of local inflammatory cells and a variety of inflammatory mediators. This initial physiological protective response can be strictly regulated, but then due to excessive inflammatory cells and mediators, a waterfall-like cascade reaction occurs, immune homeostasis is unbalanced, proinflammatory factors such as TNF-α, IL-1β, IL-18, IL-6, and IFN-γ are released into the blood, and the local inflammatory response of the pancreas is amplified, leading to systemic immune disorders, causing systemic inflammatory response syndrome (SIRS), involving damage to tissues such as the lungs, kidneys, and liver, leading to multiple organ dysfunction syndrome (MODS). Due to the release of inflammatory mediators, the body secretes compensatory anti-inflammatory cytokines, causing compensatory anti-inflammatory response syndrome (CARS), leading to immunosuppression and secondary infection. In the early stage of SAP, inflammatory damage is mainly initiated by the release of a large number of inflammatory factors by macrophages and neutrophils. The activation of CD4+T lymphocytes causes the proliferation of memory T cells and the generation of effector function T cell subsets, and participates in the regulation of tissue inflammatory microenvironment by regulating the function of immune cells. Activated CD4+T lymphocytes initiate the activation of innate immune cells by releasing a large number of inflammatory mediators, leading to an inflammatory storm and inducing the occurrence of early SIRS in SAP. CD4+T lymphocytes can differentiate into pro-inflammatory helper T (T helper, Th) cell subsets Th1 and Th17 and anti-inflammatory Th2 subsets and regulatory T cells (Regulatory T cells, Treg). Among them, Th1 and Th17 cells can activate macrophages and neutrophils by releasing pro-inflammatory factors such as IFN-γ and IL-17, further inducing pancreatic inflammatory damage and promoting the progression of severe SAP. IL-10 released by the regulatory T cell subset Treg is a key anti-inflammatory factor in the regulation of immune microenvironment homeostasis. It can inhibit the activation and proliferation of effector T lymphocytes through cell-to-cell contact, mediate the transformation of Th1 / Th2 and the differentiation of Th17 cells, induce the M2 functional polarization of macrophages, and thus reduce inflammatory damage.
[0039] The applicant of the present invention has found that CD4+T cell immune response in pancreatic tissue is an early event of SAP and is crucial for regulating the homeostasis of the immune microenvironment of pancreatic tissue. As the "initiator" of SAP damage, pancreatic acinar cells can independently induce initial inflammation through "acinar epithelial-dendritic cell (DC) transdifferentiation" under the regulation of DC-SIGN in the early stage of SAP inflammation. The DC-like cell function of the T cell pro-inflammatory response recruits and activates CD4+T cells, resulting in an increase in the number of Th1 and Th17 cells in pancreatic tissue and a decrease in the number of Th2 and Treg cells, thereby forming a microstructure similar to a lymphoid organ or tertiary lymphoid tissue in the local tissue, forming an immune microenvironment state unique to the pancreatic tissue. Therefore, it is proposed that CD4+T cells are crucial to maintaining the homeostasis of the immune microenvironment of pancreatic tissue and are a key factor affecting the progression of SAP severity. The research of the applicant of the present invention has confirmed that by intervening in the ratio of Th1 / Th2 and Treg / Th17 cells, the homeostasis of the local immune microenvironment of pancreatic tissue can be effectively improved, and the early inflammatory damage of SAP can be alleviated.
[0040] Adipose derived stem cells (ADSCs) are a type of MSCs with self-renewal and multidirectional differentiation potentials. They mainly participate in intercellular information transmission through paracrine secretion, and extracellular vesicles (EVs) are one of the main substances secreted by them, including 30-150nm exosomes (Exosomes, Exos), 100-1000nm microvesicles (Microvesicles, MVs) and >1000nm apoptotic bodies (Apoptotic bodies). Due to the overlap between the physical and chemical properties of the above three, they cannot be completely separated in terms of structure or function. More and more studies have classified them into one category, namely extracellular vesicles (EVs).
[0041] EVs are double-layer nanovesicles, and their membranes are mainly composed of ceramide, cholesterol, phosphoglycerides and long-chain free fatty acids. EVs contain DNA, RNA and proteins (such as integrins and enzymes), and there are specific proteins on the membrane surface for target cell recognition and attachment (including annexin, tetraspanin and raft lipoproteins, etc.). EVs are widely present in the human body. They are not cells, but they are part of cells. Therefore, they have the physical and chemical properties of parent cells and have extremely high biocompatibility. These characteristics make it play an important role in intercellular communication and maintenance, and disease progression. ADSCs-EVs can enter the receptor cells through endocytosis, membrane fusion or ligand binding to activate signal pathways, and deliver the bioactive substances such as proteins, lipids or RNA they carry to the cytoplasm of the receptor cells, thereby regulating the pathological state of the receptor cells and repairing tissue damage. Compared with stem cell therapy, ADSCs-EVs have the advantages of safety, long-term effectiveness, and easy storage and transportation, and its clinical application prospects are broader.
[0042] The applicant of the present invention has found through experiments that human adipose stem cells derived extracellular vesicles (hADSCs-EVs) have an immunomodulatory effect on Treg cells induced and stimulated in vitro. The method of tail vein injection of hADSCs-EVs to treat SAP mice can upregulate the number of CD4+CD25+Foxp3+Treg cells in pancreatic tissue and the level of anti-inflammatory factor IL-10, inhibit the number of CD4+IFN-γ+Th1, CD4+IL-17A+Th17, M1 macrophages and the level of pro-inflammatory factors INF-γ, IL-1β, IL-18, and alleviate inflammatory damage. At the same time, through tissue morphology and functional evaluation, it was found that hADSCs-EVs treatment can significantly improve multi-organ damage such as pancreas, kidney and lung caused by SAP.
[0043] The present invention proposes that hADSCs-EVs can improve the immune microenvironment of pancreatic tissue in the early stage of SAP, thereby promoting tissue repair and improving organ function after SAP injury, thereby reducing the mortality rate of SAP mice.
[0044] The present invention will be further described below in conjunction with specific embodiments. It should be understood that these embodiments are only used to illustrate the present invention and are not intended to limit the scope of protection of the present invention. The practicable parameter ranges defined by the present invention are not subject to the limitations specifically exemplified in the following embodiments. The improvements and adjustments made by those skilled in the art in practical applications according to the present invention still belong to the scope of protection of the present invention.
[0045] Example 1
[0046] Extraction of human adipose-derived stem cell-derived exosomes (hADSCs-EVs)
[0047] hADSCs cells (hADSCs cells were derived from the National Stem Cell Transformation Resource Bank, ZB10DGAC) were inoculated in a 10 cm culture dish and cultured with exosome-free serum medium (the composition of the exosome-free serum medium is as follows: DF12 (DMEM / F-12 medium, Gibco, 11330-032) + 10% exosome-free serum (Vivacell biosciences, C380110050) + 1% double anti-penicillin / streptomycin (penicillin-streptomycin double anti-solution, Gibco, 15070063) + 10 ng / ml bFGF (basic fibroblast growth factor, STEMCELL, BX22989): Culture until the cell confluence reaches 100%, collect the supernatant, and extract hADSCs-EVs by ultracentrifugation (wherein the ultracentrifugation parameters are as follows: 2000g, 4°C, centrifugation for 30min), transfer the supernatant to a new centrifuge tube, and centrifuge again at 12000g, 4°C for 45min to remove larger vesicles. Take the supernatant, resuspend it with 20mL pre-cooled 1×PBS, filter it through a 0.45μm filter membrane, and collect the filtrate. Transfer the filtrate to a new centrifuge tube, select an ultracentrifuge rotor (ultracentrifuge model: Optima XP_CTZ19D16, rotor model: MLS50, MLA-50), and centrifuge it at 4°C and 110000g for 2h. The supernatant was removed, and the cells were resuspended in 3 mL of pre-cooled 1× PBS. A horizontal ultracentrifugation rotor was selected and ultracentrifuged again at 4°C and 110,000 g for 2 h. The supernatant was removed, and hADSCs-EVs were resuspended in 100 μL of pre-cooled 1× PBS. 5 μL of hADSCs-EVs were taken for electron microscopy, 5 μL of particle size, 20 μL of protein extraction, and 30 μL of WB. The remaining hADSCs-EVs were placed at -80°C for later use.
[0048] Example 2
[0049] Identification of hADSCs-EVs
[0050] (1) Transmission electron microscopy (TEM) identification of hADSCs-EVs morphology
[0051] Take out 5 μL of hADSCs-EVs obtained by ultracentrifugation and dilute to 10 μL to obtain the test sample;
[0052] 10 μL of the sample was added to the copper mesh for precipitation for 1 min, and the floating liquid was removed by filter paper. The sample was placed under a warm light until it was dry. 10 μL of phosphotungstic acid was added to the copper mesh for precipitation for 1 min, and the floating liquid was removed by filter paper. The sample was placed under a warm light until it was dry. Electron microscopy was performed at 580 kV to obtain transmission electron microscopy imaging results.
[0053] The results are as follows Figure 1 As shown, under transmission electron microscopy, negatively stained hADSCs-EVs appeared as 50-150nm cup-shaped vesicles, and their morphology was consistent with the exosome structure.
[0054] (2) Identification of hADSCs-EVs surface markers by WB
[0055] The protein concentration of the hADSCs-EVs (three groups) prepared in Example 1 was determined by BCA or Bradford method, and 20 μg of the hADSCs-EVs prepared in Example 1 was subjected to SDS-PAGE electrophoresis.
[0056] Take out the hADSCs-EVs prepared in Example 1 as a protein sample, boil at 100°C for 15 minutes in a constant temperature metal bath, and centrifuge for 5 seconds; add the protein sample and Maker to the 12% SDS-PAGE electrophoresis gel well in sequence. Run the gel at 80V until the sample runs out of the concentrated gel, and run the gel at 100V until bromophenol blue reaches the bottom of the gel. Lay the sponge pad, filter paper, methanol-soaked PVDF membrane, gel, filter paper, and sponge pad in the order of 300mA transfer. The transfer time is determined according to the size of the protein to be detected. The general rule is 1kd = 1min. After the transfer is completed, take out the PVDF membrane, soak the membrane in 5% skim milk TBST with the protein side facing up, and block for 1 hour. Use TBST primary antibody diluent containing 5% BSA to dilute the primary antibodies TSG101, CD9, CD63, and HSP90 according to the instructions, and shake gently at 4°C overnight; then wash the membrane with TBST for 10 minutes, and wash 3 times. Incubate the membrane in the secondary antibody diluted in TBST containing 5% skim milk powder for 1 hour with gentle shaking at room temperature, then wash the membrane with TBST for 10 minutes, and wash 3 times. Incubate the membrane with the prepared ECL luminescent reagent, and use scanning to detect imaging. The results are as follows Figure 2 As shown, the protein samples expressed exosome surface markers TSG101, CD9, CD63, and HSP90.
[0057] (3) NTA to identify the size and quantity of exosomes
[0058] Take out 5 μL of hADSCs-EVs obtained by ultracentrifugation and dilute to 300 μL. Use a 200 μL pipette to gently blow and mix the sample, then transfer it to a specific sample tank and place it in the detector. Use the Zetasizer Nano S nanoparticle size analyzer to detect the particle size range of the samples (setting parameters are: particle size range 50-200nm, molecular weight range: 1000-20107Dalton temperature range: 25°C, laser: 4.0mW He-Ne laser, 633nm wavelength). Each sample was analyzed continuously at least three times (3-5 times). The particle size was analyzed using Brookhaven Instruments' NanoSight NTA data analysis software, and the results are shown in the figure. Figure 3 As shown, the results showed that hADSCs-EVs conformed to the size range.
[0059] Example 3
[0060] It was verified that hADSCs-EVs reduced SAP multi-organ damage and mouse mortality by improving the imbalance of tissue immune microenvironment.
[0061] (1) Take DiR red cell membrane fluorescent dye and incubate hADSCs cells (derived from the National Stem Cell Transformation Resource Bank, ZB10DGAC) at 37°C for 2-20 minutes, discard the dye working solution, wash with culture medium 2-3 times, update the pre-warmed culture medium, incubate for 5-10 minutes, and observe under a fluorescence microscope. Collect the cell supernatant, extract exosomes according to the method in Example 1, and obtain DiR red fluorescent labeled hADSCs-EVs.
[0062] (2) CAE (50 mg / kg) was intraperitoneally injected into 6-8 week old C57BL / 6 mice 8 times a day for two consecutive days. After the last CAE injection, LPS (30 mg / kg) was intraperitoneally injected to construct a SAP mouse model. The control Sham group mice were injected with the same dose of normal saline. The SAP+EVs treatment group was immediately injected with hADSCs-EVs in (1) through the tail vein after SAP modeling. The EVs group was injected with hADSCs-EVs through the tail vein of Sham mice to verify the safety of EVs. The fluorescence intensity of red fluorescence in the liver, lung, kidney, spleen and pancreatic tissues was observed using an in vivo imager (IVISSpectrum). The results are shown in Figure 2. Figure 4 As shown, the mortality rate of mice in each group was counted and the survival curve was drawn. The results are shown in Figure 5The results showed that mice injected with hADSCs-EVs via the tail vein alone survived normally, while the 24h survival rate of SAP-induced mice was 40% and the 4d survival rate was 0. However, treatment with hADSCs-EVs via the tail vein of SAP mice increased the 24h survival rate to 80% and the 4d survival rate to 100% ( Figure 5 ).
[0063] (3) Sham, SAP, and SAP+EVs groups were set up according to the method in (2). Mice were killed 12 hours after modeling, and the liver, lung, kidney, and pancreatic tissues of mice were collected to prepare pathological sections. H&E staining was used to observe tissue pathological damage. Mouse serum samples were collected, and ELISA was used to detect the levels of amylase and lipase in mouse serum and IL-10, TGF-β, IL-17A, IFN-γ, IL-6, TNF-α, IL-1β, and IL-18 cytokines in pancreatic tissue. H&E results showed that SAP mice had significant tissue and organ damage, manifested as pancreatic acinar cell necrosis, pancreatic interstitial inflammatory cell infiltration, renal tubular epithelial cell brush border shedding, tubular lumen dilation, red and white blood cells aggregation in the renal tubular lumen to form cell casts, alveolar epithelial shedding, alveolar collapse and fusion, significant widening of alveolar septa, and liver lobule destruction. Treatment with hADSCs-EVs significantly alleviated the above tissue damage ( Figure 6 ). Pancreatic lipase and amylase are the gold standards for evaluating pancreatic damage. ELISA results showed that hADSCs-EVs treatment can significantly reduce the levels of lipase and amylase in the serum of SAP mice ( Figure 7 ). The levels of serum inflammatory cytokines were further used to evaluate the systemic inflammatory response of mice and the secretion of cytokines by various immune cell subsets. ELISA results showed that hADSCs-EVs treatment could reduce the levels of pro-inflammatory factors IFN-γ, IL-1β, and IL-18 in SAP mice, and increase the level of anti-inflammatory factor IL-10, but did not affect the levels of inflammatory factors TGF-β, IL-17A, IL-6, and TNF-α ( Figure 8 ).
[0064] (4) Preparation of pancreatic tissue single-cell suspension: The mouse pancreatic tissue was removed and minced, placed in a 6-well plate and incubated with 3 mL of digestion buffer (1 mg / mL collagenase and 0.02 mg / mL DNase added to DMEM / F12 complete medium containing 10% fetal bovine serum and 1% penicillin-streptomycin) for 2 h, then filtered through 100 μm and 75 μm cell sieves, washed twice with PBS containing 2% fetal bovine serum, and the pancreatic tissue single-cell suspension was collected for later use. According to the flow cytometry surface staining method, CD4, CD25, CXCR5, CD68, F4 / 80 antibodies and other cell surface antigens were added. For the marker molecules that need to be stained intracellularly, such as IFN-γ, IL-4, IL-17A, Foxp3, bcl-6, CD206, iNOS, Arg-1, etc., the cells were fixed and permeabilized, and then the corresponding antibodies were added for incubation. After that, the flow cytometer was used to detect and count the proportion of CD4+T cell subsets Th1, Th2, Th17, and Treg cells in the tissue, and the proportion of macrophage subsets M1 and M2 cells. The flow cytometry results showed that Treg ( Fig. 9 )、Th2( Fig.10 ) cells decreased, Th1( Fig.11 )、Th17( Fig.12 ) cells increased, M1 macrophages increased, and M2 macrophages decreased ( Fig.13 ), while hADSCs-EVs treatment could significantly reverse the above changes. Figure 8 The changes in inflammatory factors suggest that hADSCs-EVs may promote Treg cell differentiation, leading to increased secretion of the anti-inflammatory factor IL-10, regulate the imbalance of tissue immune microenvironment, thereby alleviating multiple organ damage and reducing mouse mortality.
[0065] Example 4
[0066] hADSCs-EVs improve the imbalance of tissue immune microenvironment by regulating Treg cell differentiation.
[0067] (1) Take DiO green cell membrane fluorescent dye and incubate hADSCs cells (derived from the National Stem Cell Transformation Resource Bank, ZB10DGAC) at 37°C for 2-20 minutes, discard the dye working solution, wash with culture medium 2-3 times, renew the pre-warmed culture medium, incubate for 5-10 minutes, and observe under a fluorescence microscope. Collect the cell supernatant, extract exosomes according to the method in Example 1, and obtain DiO green fluorescent labeled hADSCs-EVs.
[0068] (2) Isolation from the spleen of wild-type mice using flow cytometry CD4+T cells were treated with 5μg / mL anti-CD3 and 2μg / mL anti-CD28, and then induced to differentiate into Treg cells using Inducer (inducer: 5ng / mL TGF-β+10ng / mL IL-2+5μg / mLanti-IFN-γ+5μg / mL anti-IL-4). DiO green fluorescent-labeled hADSCs-EVs were co-incubated with Treg cells, and the uptake of hADSCs-EVs by Treg cells was observed under a fluorescence microscope ( Fig.14 hADSCs-EVs (green) are taken up by Treg cells).
[0069] (3) Isolation from the spleen of wild-type mice CD4+T cells were co-cultured with 10ug / mL, 20ug / mL, and 30ug / mL hADSCs-EVs, and the mRNA levels of Foxp3, a core transcription factor for Treg differentiation, and IL-10 were detected. PCR results showed that stimulation with 30ug / mL hADSCs-EVs could independently induce CD4+T cells differentiate into Treg cells and promote the production of anti-inflammatory factor IL-10 ( Fig.15 ).
[0070] (4) Isolation from the spleen of wild-type mice CD4+T cells were first induced to differentiate into Treg using Inducer, and then co-incubated with 10ug / mL, 20ug / mL, and 30ug / mL hADSCs-EVs to detect the mRNA levels of Foxp3, a core transcription factor for Treg differentiation, and IL-10. PCR results showed that hADSCs-EVs induced Treg differentiation and IL-10 production in a dose-dependent manner ( Fig.16 ).
[0071] (5) Flow cytometry was used to further verify the effects of hADSCs-EVs on Induction of CD4+T cells. CD4+T cells were co-cultured with 10ug / mL, 20ug / mL, and 30ug / mL hADSCs-EVs, and T cell differentiation was detected by flow cytometry. The results showed that 30ug / mL hADSCs-EVs could significantly induce the differentiation of CD4+Foxp3+Treg ( Fig.17 ), but had no effect on CD4+IL-4+Th2 cells ( Fig.18). Combined with 7.2, it is suggested that hADSCs-EVs induce Treg cell differentiation by upregulating Foxp3 and promoting the production of IL-10, thereby exerting an anti-inflammatory effect, and then affecting the changes in the proportions of CD4+T cell subsets (Treg, Th2, Th1, Th17) and macrophage subsets (M1, M2), improving the imbalance of tissue immune microenvironment, and alleviating inflammatory damage in SAP mice.
[0072] The above disclosure is only the preferred embodiment of the present invention, and the preferred embodiment does not describe all the details in detail. It should be understood that these embodiments are only used to illustrate the present invention but not to limit the scope of protection of the present invention. The present invention is only limited by the claims and their full scope and equivalents.
[0073] This specification selects and specifically describes these embodiments in order to better explain the principles and practical applications of the present invention, so that those skilled in the art can make good use of the present invention. Under the guidance of the present invention and the above-mentioned embodiments, it is easy for those skilled in the art to foresee that each raw material or its equivalent replacement, each processing method or its equivalent replacement listed or exemplified in the present invention can realize the present invention, and the upper and lower limit values and interval values of the parameters of each raw material and processing method can realize the present invention, and the embodiments are not listed one by one here.
Claims
1. The use of human adipose stem cell-derived exosomes hADSCs-EVs in the preparation of a drug for treating severe acute pancreatitis, characterized in that: The human adipose stem cell-derived exosomes hADSCs-EVs are prepared by the following steps: hADSCs cells are inoculated in a culture dish, cultured using a serum culture medium without exosomes until the cell confluence reaches 100%, the supernatant is collected, ultracentrifuged, the precipitate is retained, and the precipitate is resuspended to obtain adipose stem cell-derived exosomes hADSCs-EVs; the serum culture medium without exosomes includes DMEM / F-12 culture medium, exosome-free serum, penicillin-streptomycin double antibody solution and basic fibroblast growth factor.
